Background-The coronary artery calcium (CAC) score predicts future coronary heart disease (CHD) events and could be used to guide primary prevention interventions, but CAC measurement has costs and exposes patients to low-dose radiation. Methods and Results-We estimated the cost-effectiveness of measuring CAC and prescribing statin therapy based on the resulting score under a range of assumptions using an established model enhanced with CAC distribution and risk estimates from the Multi-Ethnic Study of Atherosclerosis. Ten years of statin treatment for 10 000 55-year-old women with high cholesterol (10-year CHD risk, 7.5%) was projected to prevent 32 myocardial infarctions, cause 70 cases of statin-induced myopathy, and add 1108 years to total life expectancy. Measuring CAC and targeting statin treatment to the 2500 women with CAC>0 would provide 45% of the benefit (+501 life-years), but CAC measurement would cost $2.25 million and cause 9 radiation-induced cancers. Treat all was preferable to CAC screening in this scenario and across a broad range of other scenarios (CHD risk, 2.5%-15%) when statin assumptions were favorable ($0.13 per pill and no quality of life penalty). When statin assumptions were less favorable ($1.00 per pill and disutility=0.00384), CAC screening with statin treatment for persons with CAC>0 was cost-effective (<$50 000 per quality-adjusted life-year) in this scenario, in 55-year-old men with CHD risk 7.5%, and in other intermediate risk scenarios (CHD risk, 5%-10%).
L owering cholesterol with 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins) reduces risk of cardiovascular disease (CVD) in patients who have not yet experienced a CVD event (ie, primary prevention). 1 Using statins in otherwise healthy individuals, however, has financial costs, may be inconvenient or undesirable to patients for a variety of reasons, and exposes patients to risks of adverse drug effects. [2] [3] [4] Patients at higher CVD risk are more likely to benefit from statins, and current guidelines recommend a more aggressive approach to statin prescribing in these patients, 5 but our ability to predict CVD using traditional risk factors (eg, Framingham-based risk equations) is imperfect. 6, 7 Whether additional risk stratification testing might be useful and cost-effective for guiding statin therapy remains controversial.
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The coronary artery calcium (CAC) score is an indicator of coronary atherosclerosis measured by computed tomography scanning that could be used to guide statin therapy. Although CAC is correlated strongly with traditional risk factors, it provides substantial additional information about an individual's risk for future coronary heart disease (CHD) events, including myocardial infarction (MI), angina, and CHD death [11] [12] [13] and helps improve risk classification 13 more than other currently available nontraditional risk factors.
14 Measurement of the CAC score, however, adds front-end costs and exposes patients to small doses of ionizing radiation. 15 It is unclear whether using CAC to guide statin therapy might provide significant net health benefits to patients, and whether such use would be cost-effective. We estimated the costs and effectiveness of using CAC testing to guide primary prevention with statin therapy using an established decision model that was enhanced with CAC parameters from the Multi-Ethnic Study of Atherosclerosis (MESA). 11, 16 Unlike previous efforts, [17] [18] [19] [20] [21] our model carefully accounts for the expected CAC distribution in a range of specific clinical scenarios 16 and provides systematic analyses of CAC testing strategies with different treatment thresholds (versus simply prescribing statins or not) under a range of assumptions about statin therapy and CAC scan cost, effectiveness, and adverse effects. 22 
Methods
Overview and Model Structure
The University of North Carolina-Research Triangle Institute CVD Prevention Model is a state-transition simulation model that can be used to compare incidence of CVD, mortality, quality of life, and costs with and without a prevention intervention. 23, 24 In the model, a specific clinical scenario is defined by age, sex, and CVD risk factors. Persons with these characteristics begin in the healthy state and then may transition every 12 months. Separate states explicitly model first and subsequent years after myopathy, angina, MI, and stroke; costs, quality of life, and mortality rates differ in each state. Total costs and quality-adjusted life-years (QALYs) were calculated (discounting at 3%/y for costs and utilities) over a lifetime horizon.
Our primary outcome measure is the incremental cost-effectiveness ratio (ICER), measured in $/QALY. For illustration purposes, we indicate preferred strategies under the assumption that society is willing to pay ≤$50 000 per QALY, but continuous ICER values are provided throughout. Model parameters were varied in 1-way and global probabilistic analyses. Materials in the Data Supplement describe the model parameters (Table I in the Data Supplement) and provide additional Methods detail. This research did not involve human subjects or animals and does not require institutional review board approval.
Prevention Strategies Compared: To Scan or Not to Scan?
The model is used to compare 5 different interventions: 2 strategies where statin prescribing does not depend on results of a CAC scan (treat none and treat all), and 3 strategies where a CAC scan is ordered (1 time only, with attendant costs and radiation exposure), and statins are prescribed only if the CAC score is above a given threshold (treat if CAC>300, treat if CAC>100, and treat if CAC>0). Statin prescribing is assumed to be differential for 10 years, but accrual of costs and QALYs is simulated across a full lifetime horizon to fully account for the consequences of a life saved or MI prevented by statins during those first 10 years of differential treatment.
Base-Case Scenarios
Our base-case clinical scenario is a 55-year-old woman with total cholesterol of 221 mg/dL, high-density lipoprotein cholesterol of 40 mg/dL (high cholesterol), and no other CHD risk factors (systolic blood pressure, 120 mm Hg without medications; no smoking; or diabetes mellitus). These risk factors yield an average Framingham-derived 10-year risk for angina, MI, or CHD death of 7.5% 25 (used for state-transition probabilities along with a stroke risk of 0.9%), and they also determine the CAC score distribution (see below). Alternate clinical scenarios varying age, sex, and overall risk are also considered.
Based on preliminary results showing sensitivity to statin-related parameters, we present 2 base-case statin scenarios in parallel throughout the article. The first assumes that statins can be obtained at a cost of $0.13 per pill (available through $4/mo prescribing programs at some large discount retailers) 26 and that taking a statin pill every day is not associated with any reduction in quality of life (favorable statin assumptions); the second scenario assumes a higher cost of $1.00 per pill (most statin users do not avail themselves of $4/mo programs) 26 and a quality of life penalty (disutility) of 0.00384 associated with every year of statin use, which is equivalent to trading away 2 weeks of perfect health to avoid 10 years on statins 27 (less favorable statin assumptions). The quality of life penalty modeled here represents inconvenience, reduction in self-conception of health, and any other reason that a patient might prefer not to take a pill daily; statin-induced myopathy is modeled separately.
CAC Score Testing Parameters
Direct CAC scan costs were obtained from the American Medical Association's Relative-Based Resource Value Scale. 28 We added the cost of a physician visit 28 for scan interpretation and average workup costs for incidental noncardiac findings 29, 30 (see Materials in the Data Supplement).
The prevalence of CAC and expected distribution of the CAC score, conditional on CHD risk factors, is a critical parameter 31 that we estimated using a multivariable model derived from the MESA baseline examination. 16 We used this model to estimate the proportion of scores falling into categories of 0, 1 to 100, 101 to 300, and >300, and then to estimate post-test risk for angina, MI, and CHD death in these categories using CAC-specific relative risks from MESA 11 and previously described methods. 16 We assumed that the risk of stroke did not vary with CAC.
We assumed an average radiation dose of 2.3 mSv from each scan 15 and an excess relative risk of 0.001/mSv for all-cause cancer 15, 32 (see Materials in the Data Supplement).
Statin Assumptions
Along with the cost and disutility assumptions described above, we assumed that (1) statin use triggers 1 additional physician visit and lipid panel per year; (2) standard dose statins are associated with relative reductions in risk of MI (26%; ie, relative risk, 0.74), angina (26%), stroke (15%), and CHD death (20%) 1 (Materials in the Data Supplement); (3) statins cause myopathy 2 (with associated cost, mortality, and disutility for 1 year, 27 which then leads to statin discontinuation); and (4) imperfect statin adherence, 33 with discontinuation events occurring immediately. Hepatitis and liver function testing costs were not included.
2,34
Although there is evidence that statins cause diabetes mellitus, 4 
WHAT IS KNOWN
• The coronary artery calcium score predicts coronary heart disease events but costs money and exposes the patient to some radiation.
• Statins can prevent coronary heart disease events.
• It is unclear when it might be cost-effective to order a coronary artery calcium score test and use the results to decide whether to prescribe a statin to prevent coronary heart disease events.
WHAT THE STUDY ADDS
• When statins are inexpensive and do not cause a significant reduction in quality of life, it is better to simply prescribe the medication without ordering a coronary artery calcium score test.
• When statins are expensive and reduce quality of life, ordering a coronary artery calcium score test and using the results to guide statin therapy can be cost-effective.
the cardiovascular benefits outweigh the risks, at least in the short term, 35 and the statin trial results on which we base our statin efficacy assumptions account for this effect. Alternate assumptions about statin-associated cost and health impact from these factors or others are simulated easily by increasing overall statin cost and disutility.
Results
Base-Case Scenario
Ten years of statin treatment for 10 000 55-year-old women with high cholesterol (10-year CHD risk, 7.5%; stroke risk, 0.9%) was projected to prevent 32 lifetime MIs, cause 70 cases of statin-induced myopathy, and add 1108 years to total life expectancy (treat all versus treat none). Targeting statin treatment to the 2500 women with CAC>0 (treat if CAC>0) would provide 45% of the benefits (+501 life-years) but would require CAC screening for all 10 000, which would cost $2.25 million and cause 9 radiation-induced cancers (Table 1) .
With favorable statin assumptions ($0.13 per pill and no quality of life penalty), the costs of statin treatment are low and almost entirely offset by healthcare savings from prevented events. Targeted statin prescribing, therefore, would not result in substantial savings and would not be a rational alternative to treat all (Table 1) .
Under less favorable assumptions, statin costs ranged from $3.46 to $28.91 million, and these costs were not completely offset by healthcare savings from prevented events; with more persons treated with statins, both costs and QALYs increased. Treat if CAC>100 and >300 identified relatively small numbers of persons to treat with statins and did not generate enough QALYs to offset the testing costs compared with competing strategies. In contrast, treat if CAC>0 was reasonable (not dominated), producing more QALYs than treat none at a cost of $18 000 per QALY. Treat all produced even more QALYs but at a much higher price ($78 000 per QALY; Table 1) .
A parallel analysis for 55-year-old men at 7.5% CHD risk (stroke risk, 1.2%) yielded similar results (Table II in the Data  Supplement) . Men were more likely to have CAC (39% with CAC>0), more likely to have an MI or a stroke, and less likely to have angina as a first event and generally had lower life expectancy, but incremental cost-effectiveness ratios were nearly identical ($19 000 per QALY for treat if CAC>0 compared with treat none; and $80 000 per QALY for treat all compared with treat if CAC>0).
Sensitivity Analyses for Base-Case Scenario
With favorable statin assumptions, treat all was cost-saving or relatively cost-effective (<$50 000 per QALY) in 55-year-old women with high cholesterol even with wide variation of other model parameters in 1-way sensitivity analyses (Table 2) and with global probabilistic sensitivity analyses (Figure) .
With unfavorable statin assumptions, the treat if CAC>0 strategy remained relatively cost-effective (≤$50 000 per QALY; see Table III in the Data Supplement for ICER values) in 1-way sensitivity analyses that varied the statin myopathy rate, the statin discontinuation rate (unless it is ≥75%), statin efficacy (unless it is reduced by ≥50%), CAC scan costs (unless direct costs are ≥$600), CAC-specific relative risk estimates (unless they are reduced by ≥50%), the degree of radiation exposure from the CAC scan (≤10.5 mSv), or assumptions about the downstream mortality risk after CVD events (Table 2) . Preference for the treat if CAC>0 strategy was somewhat sensitive, however, to global probabilistic parameter variation and sensitive to society's willingness-to-pay threshold (Figure) .
When statin costs are even higher ($4.00 per pill) or disutility larger (0.02, equivalent to trading away 10 weeks of perfect health to avoid 10 years on statins), treat none is preferred (Table 2) .
Alternate Clinical Scenarios
With favorable statin assumptions and using a willingnessto-pay threshold of $50 000 per QALY, the treat all strategy was preferred in every clinical scenario that we simulated, including men and women at lower age and lower risk (Table 3) . With less favorable statin assumptions, the treat if CAC>0 strategy was preferred in most scenarios where CHD risk was intermediate (5%-10%) but with some variation by age and sex (Table 3) . Tables V to VIII in the Data Supplement demonstrate shifts in the window of cost-effectiveness for CAC testing with altered assumptions about statin efficacy, cost, and disutility. A CAC threshold >0 (treat if CAC>100) was cost-effective only in edge cases, usually when statin cost or disutility was assumed to be quite high (Tables V to VIII in the Data Supplement); otherwise, the CAC=0 threshold was preferred. Treat if CAC>300 was dominated in every scenario we analyzed.
Discussion
Statins are effective at preventing CHD events across a broad range of CHD risk, 1 including risk levels well below current statin treatment thresholds, 5 and are considered to be safe.
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Our results indicate that when they are also inexpensive ($0.13 per pill, $4/mo) and easy to use (ie, no quality of life penalty), obtaining a CAC scan to prevent some patients from having to take a statin is not a cost-effective approach. Under these assumptions, which represent a likely scenario in the current generic statin era, our model suggests that it is better not to order the test and instead simply to treat with statins (treat all). When statins cost more or substantially diminish quality of life, our analyses show that CAC testing can be a cost-effective way of identifying patients who are at low CHD risk and therefore have little to gain from these medications. Our base-case scenario illustrates such a situation: for a 55-year-old woman with high cholesterol and 10-year CHD risk of 7.5%, whose insurance would pay $1 per pill for her statin prescription and who would much prefer not to take them (disutility, 0.00384; ie, she would be willing to trade 2 weeks of perfect health to avoid 10 years of statin therapy), our analysis demonstrates that a strategy of obtaining a CAC scan first and only treating her with statins if the scan demonstrates some evidence of calcified atherosclerotic plaque (ie, CAC>0) is relatively cost-effective. This decision would only be rational, however, if society were willing to pay ≥$18 000 per QALY but not >$78 000 per QALY. These threshold values, and thus the potential cost-effectiveness of CAC testing, depend critically on statin assumptions (cost and disutility) and on the specifics of the clinical scenario (age, sex, and risk factor profile), which drive both CHD risk and CAC prevalence.
Our results are generally consistent with prior costeffectiveness analyses. Two recent analyses 20, 21 simulated CAC testing and reclassification of a population of intermediate risk persons (using 2 different population/community-based †In the favorable statin assumptions scenario, statins cost $0.13 per pill and have no disutility. In the less favorable statin assumptions scenario, statins cost $1.00 per pill and have disutility of 0.00384, equivalent to 2 wk of perfect health traded away to avoid 10 y on statins. Note that total statin costs account for discontinuation after myopathy and addition of statin therapy in all strategies for secondary prevention dependent on state membership.
‡Preferred strategy under the given assumptions if society is willing to pay ≤$50 000 per QALY.
cohort studies) with statin 20, 21 and antihypertensive 21 treatment intensity based on post-test risk. One assumed inexpensive statins ($0.13 per pill) and found results consistent with our favorable statin assumptions scenario (ie, treat all dominated), 20 and the other used higher statin costs ($1.56 per pill) and found cost-effectiveness of CAC screening, at least in men, 21 consistent with our unfavorable statin assumptions scenario. Unlike either of these analyses, ours considered more focused, specific clinical scenarios instead of averaging results over the entire intermediate risk population. Our results suggest that the cost-effectiveness of CAC testing varies, even among persons at intermediate risk, depending on the specifics of the clinical scenario. Older cost-effectiveness analyses incorporated follow-up ischemia testing after a positive CAC scan 18, 19 (which is not currently recommended) 12 and used assumptions about CAC risk stratification that predate MESA and other modern cohort studies, [17] [18] [19] and are therefore not directly comparable. CAC indicates coronary artery calcium; CHD, coronary heart disease; CVD events, cardiovascular disease events; and treat if CAC>X, test for CAC, and treat with statins if the CAC score is >X.
*The base-case clinical scenario is a 55-year-old woman with total cholesterol of 221 mg/dL, high-density lipoprotein cholesterol of 40 mg/dL, and systolic blood pressure of 120 mm Hg without medications who does not smoke or have diabetes mellitus.
†Base-case scenarios. Statin price and disutility were varied in 1-way sensitivity analyses within each scenario to show the independent contribution of each factor. For 1-way analyses where a different parameter is varied, we show results for both favorable and unfavorable statin assumption scenarios. In the favorable statin assumptions scenario, statins cost $0.13 per pill and have no disutility. In the less favorable statin assumptions scenario, statins cost $1.00 per pill and have disutility of 0.00384, equivalent to 2 wk of perfect health traded away to avoid 10 y on statins.
‡Statin efficacy (relative risk reductions for myocardial infarction, angina, CHD death, and stroke), CAC scan relative risks (for CHD events based on the CAC score), and all-cause mortality relative risks after CVD events (risk of death multipliers in post-CHD and stroke event states) were varied from the basecase assumptions (see Table I in the Data Supplement) simultaneously by the percentage reduction shown, after conversion to the log scale. Statin efficacy relative risks were also increased in sensitivity analyses given that larger relative risks were observed for lower risk participants in our meta-analysis source for statin efficacy. Our results are also consistent with prior cost-effectiveness analyses showing that statin therapy can be cost-effective even in lower risk patients, assuming it remains efficacious, if it is inexpensive and does not significantly reduce quality of life. 27, 36, 37 Although $4/mo programs available at discount pharmacy outlets should provide access to low-cost statins, most Americans do not avail themselves of these programs, 26 and the costs of even generic statins are substantially higher at retail pharmacies. 27, 36 The decrement in quality of life associated with statin use is similarly hard to parameterize for cost-effectiveness modeling. Patients often express a preference not to take statins, which presumably reflects an expected impact on quality of life; but it is difficult to quantify that impact for any given individual, and there is wide variation between individuals and within individuals over time (and with experience and education). Our approach, though imperfect, is consistent with prior work, 38 and current guidelines 5 suggest that patient preferences and quality of life are important to consider when making decisions about statin prescribing and CAC testing. The cost-effectiveness of CAC testing is also somewhat sensitive to assumptions about the effectiveness of risk stratification provided by the CAC test. According to our best estimates from MESA 11 (used for these analyses), a previous meta-analysis, 39 and recent results from other cohort studies, [40] [41] [42] the relative risks associated with high CAC scores are large. With degradation in those relative risk estimates, CAC testing is no longer cost-effective (Table 2) . This degradation might occur if scanning technique and interpretation are lower quality in practice than they have been in research studies, or if research estimates of CAC prediction were otherwise overoptimistic, such as might occur from the lack of blinding to CAC scores that has been common in cohort studies. This sensitivity to assumptions creates a powerful rationale for real-world effectiveness testing with a clinical trial, as has been proposed 43 ; such a trial, however, would be expensive and would take many years to complete.
Our finding that the >0 CAC threshold strategy dominates higher CAC score thresholds is somewhat surprising. Higher CAC scores are associated with substantially higher relative risk for CHD (Table I in the Data Supplement), and anecdotes suggest that higher scores are often used in clinical practice for decision making. The low prevalence of high CAC scores, however, makes these high treatment threshold strategies inefficient (ie, the number needed to scan is too high). Although surprising, our findings are consistent with prior commentary on this issue. 44 Our analysis was limited in several ways. We used estimates of statin efficacy from a meta-analysis that included patients with moderately high CHD risk (Materials in the Data Supplement), 1 but we applied those efficacy estimates in scenarios where risk is lower and the evidence for statin therapy effectiveness is less established. Our results were robust to substantial degradation in statin efficacy but clearly would not hold if statins were ineffective in any given scenario. The excess cancer caused by radiation may vary with age, sex, scan technique, and other factors, 15 ,32 and radiation
Figure.
Probability of cost-effectiveness of treat all, treat none, and coronary artery calcium (CAC) screening strategies at different willingness-to-pay thresholds. These acceptability curves illustrate probabilistic results from 10 000 model runs of the base-case clinical scenario (a 55-year-old woman with high cholesterol), under both favorable and unfavorable statin assumption scenarios, that account for the uncertainty in parameter estimates described in Table I in the Data Supplement. The decision to measure CAC is sensitive to the willingness-to-pay threshold when unfavorable assumptions about statins are used. A disutility of 0.00384 is equivalent to 2 weeks of perfect health traded away to avoid 10 years on statins. QALY indicates quality-adjusted life-years.
may also induce a small increase in CHD rates. 45 We did not model these intricacies, but our analyses reveal little sensitivity to this parameter. Given the lower prevalence of CAC in non-white populations, 46 we would expect some differences in cost-effectiveness across race/ethnicity but did not attempt these analyses. We illustrated our results by indicating which strategy would be preferred if a simple (and traditional/mythical) 47 willingness-to-pay threshold of $50 000 per QALY was used by policymakers. Some have suggested that a higher threshold is more consistent with societal values, 48 or that using any simple threshold is unrealistic. 47 We agree and have provided continuous ICER values throughout to enable alternate illustrations and interpretation. We did not attempt to model the possibility that CAC testing might stimulate statin adherence, or to analyze other uses of CAC testing, such as to guide aspirin or antihypertensive therapy, to screen symptomatic patients, repeated use over time, etc.
Our cost-effectiveness analysis supports a limited role for CAC testing in asymptomatic persons. When statins are expected to be effective, safe, and inexpensive, and the patient does not have a strong preference against taking the medication, our analyses suggest that the decision to prescribe a statin is relatively straightforward and that CAC testing is neither necessary nor cost-effective. The decision to use a statin, however, is often difficult for clinicians and patients. In these settings, the additional information about CHD risk that CAC testing provides can be worth the additional expense and radiation exposure that comes with the test. *The preferred strategy is either cheaper than less effective alternatives or costs <$50 000 per additional QALY gained over the less effective alternatives; if there is a more effective alternative, it costs >$50 000 per additional QALY gained.
†In the favorable statin assumptions scenario, statins cost $0.13 per pill and have no disutility. In the less favorable statin assumptions scenario, statins cost $1.00 per pill and have disutility of 0.00384, equivalent to 2 wk of perfect health traded away to avoid 10 y on statins.
‡The 10-year Framingham-derived risk for angina, myocardial infarction, CHD death, or stroke, estimated using Framingham-based equations, 25 was manipulated for different scenarios by modifying conventional risk factors, particularly total and high-density lipoprotein cholesterol. For the risk factor levels used in each scenario and all relevant incremental cost-effectiveness ratios, see Table IVA and IVB in the Data Supplement.
§Base-case clinical scenario. Results from this scenario are shown in detail in Tables 1 and 2. 
